ACET — Adicet Bio Cashflow Statement
0.000.00%
Last trade - 00:00- $55.42m
- -$120.89m
- 11
- 53
- 40
- 26
Annual cashflow statement for Adicet Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -36.7 | -62 | -69.8 | -143 | -117 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 7.42 | 15.5 | 19.7 | 42.6 | 23.8 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -13.3 | -6.05 | 2.74 | 0.252 | -5.53 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -41.6 | -51.1 | -44.8 | -93.7 | -92.4 |
| Capital Expenditures | -0.99 | -13 | -16.8 | -4.46 | -1.12 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 116 | 10.3 | 0 | — | -118 |
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 115 | -2.8 | -16.8 | -4.46 | -119 |
| Financing Cash Flow Items | -0.157 | -0.261 | -3.6 | -0.15 | -0.141 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 0.303 | 243 | 41.5 | 0.236 | 111 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 74 | 189 | -20 | -97.9 | -100 |